Prostate Cancer Clinical Trials in New York, New York

66 studies are recruiting for prostate cancer in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

  1. [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate or Salivary Gland Cancer

    This study will use PET scans, which is a type of x-ray test that uses a radiotracer, to see whether these scans may be better able to find places in the body where your prostate cancer may have spread.

    Stage
    Not phased
    Ages
    Any age
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT00588185 on ClinicalTrials.gov

  2. Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

    The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Mount Sinai Doctors Urology Faculty Practice, New York, New York
    Locations
    34 in total
    Run by
    Clarity Pharmaceuticals Ltd

    See if you can join NCT06056830 on ClinicalTrials.gov

  3. Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer

    For this study, high risk prostate cancer patients with lower risk ARTERA scores will be treated with 6 months of Androgen Deprivation Therapy (ADT) in conjunction with dose escalated radiotherapy to the prostate and nodes. Specifically, patients enrolled in this study will undergo one of several d…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    NYU Langone Health, New York, New York
    Run by
    NYU Langone Health

    See if you can join NCT07801664 on ClinicalTrials.gov

  4. PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound

    The purpose of this study is to compare the sensitivity of PSMA PET/MRI and standard MRI in detecting focal therapy failure in the prostate one year after High-Intensity Focused Ultrasound (HIFU) treatment. Specifically, the study aims to evaluate whether PSMA PET/MRI offers a higher sensitivity th…

    Stage
    Not phased
    Ages
    40 to 95
    Site
    NYU Langone Health, New York, New York
    Run by
    NYU Langone Health

    See if you can join NCT07184970 on ClinicalTrials.gov

  5. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09 July 2025), only Parts 4A expansion, 6, and 7 a…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    57 in total
    Run by
    Amgen

    See if you can join NCT04221542 on ClinicalTrials.gov

  6. A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

    This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan-Kettering Cancer Center (Mskcc), New York, New York
    Locations
    19 in total
    Run by
    Pathos AI, Inc.

    See if you can join NCT06785636 on ClinicalTrials.gov

  7. Prospective Database of Clinical Outcomes Following Cryotherapy for Ablation of Clinically Localized Prostate Cancer

    This will be a prospectively maintained research database. The purpose is to record baseline parameters and treatment outcomes following of Cryotherapy for ablation of clinically localized prostate cancer.

    Stage
    Not phased
    Ages
    40 to 85
    Site
    NYU Langone Health, New York, New York
    Run by
    NYU Langone Health

    See if you can join NCT07184957 on ClinicalTrials.gov

  8. A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer

    The purpose of this study is to find out if Meaning-Centered Psychotherapy for Latinos (MCP-L) helps reduce anxiety and depression and improves quality of life compared to cognitive behavioral therapy (CBT). Investigators also want to learn what participants and providers think about the therapy, i…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    2 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07225309 on ClinicalTrials.gov

  9. Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation

    Many reports of clinical outcomes following treatment of localized prostate cancer suffer from lack of prospective long-term data using objective and validated outcome instruments. The purpose of this research database is to prospectively collect data to assess treatment related complications, onco…

    Stage
    Not phased
    Ages
    40 to 95
    Site
    NYU Langone Health - Tisch Hospital, New York, New York
    Locations
    2 in total
    Run by
    NYU Langone Health

    See if you can join NCT07203482 on ClinicalTrials.gov

  10. Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

    This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients w…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Investigative Site #103, New York, New York
    Locations
    18 in total
    Run by
    MOMA Therapeutics

    See if you can join NCT06545942 on ClinicalTrials.gov

  11. PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

    1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radiation therapy for prostate cancer, as compared to standard th…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    6 in total
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT06274047 on ClinicalTrials.gov

  12. A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

    The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant prostate cancer (mCRPC).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Columbia University, New York, New York
    Locations
    12 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06457919 on ClinicalTrials.gov

  13. A Study of Lower Dose Radiation Therapy for People With Prostate Cancer

    The purpose of this study is to see whether giving a lower (de-escalated) dose of radiation therapy to some parts of the prostate can reduce side effects compared to giving the same (uniform) dose of radiation therapy to the whole prostate.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07635238 on ClinicalTrials.gov

  14. Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

    This is a phase I dose-escalation study of 225Ac-J591 administered together with 177Lu-PSMA small molecule. Both drugs are designed to deliver radiation to prostate cancer cells; they are known as radionuclide conjugates (radiation linked to antibodies/molecules that recognize prostate cancer cells…

    Stage
    Phase 1
    Ages
    18 to 99
    Site
    Weill Cornell Medicine New York Presbyterian, New York, New York
    Locations
    2 in total
    Run by
    Weill Medical College of Cornell University

    See if you can join NCT04886986 on ClinicalTrials.gov

  15. The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer

    The purpose of this study is to see whether using the copper-64 (64Cu) or zirconium-89 (89Zr) radiolabeled PSMA-targeting C' dot tracer, termed 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots or 89Zr-DFO-PSMAi-PEG-Cy5.5-C' dots, is a safe way to identify tumor cells before and during surgery for prostate cancer.…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    2 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04167969 on ClinicalTrials.gov

  16. CUIMC Focal Therapy Registry

    Patients undergoing high intensity focused ultrasound (HIFU) or irreversible electroporation (IRE) for prostate cancer will be invited to consent to have their data collected in a detailed comprehensive system to record and store patient, disease, and treatment-related characteristics. No treatment…

    Stage
    Not phased
    Ages
    40 to 85
    Site
    Columbia University Irving Medical Center, New York, New York
    Run by
    Columbia University

    See if you can join NCT07623941 on ClinicalTrials.gov

  17. International Registry for Men With Advanced Prostate Cancer (IRONMAN)

    Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry an…

    Stage
    Not phased
    Ages
    21 and older
    Site
    Columbia University Medical Center, New York, New York
    Locations
    121 in total
    Run by
    Prostate Cancer Clinical Trials Consortium

    See if you can join NCT03151629 on ClinicalTrials.gov

  18. Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

    To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Weill Cornell Medicine - New York - Presbyterian Hospital, New York, New York
    Locations
    21 in total
    Run by
    Blue Earth Therapeutics Ltd

    See if you can join NCT05413850 on ClinicalTrials.gov

  19. Brodalumab in the Treatment of Immune-Related Adverse Events

    The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Columbia University Irving Medical Center, New York, New York
    Run by
    Brian Henick, MD

    See if you can join NCT06673329 on ClinicalTrials.gov

  20. Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr

    This study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermediate-risk prostate cancer.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Weill Cornell Medicine - New York Presbyterian Hospital, New York, New York
    Locations
    4 in total
    Run by
    Weill Medical College of Cornell University

    See if you can join NCT05948657 on ClinicalTrials.gov

  21. Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

    The goal of this study is to obtain safety data, establish dose parameters, and effectiveness of treatment for the SpectraCure P18 System with IDOSE®, together with verteporfin for injection (VFI) as photosensitizer, for the treatment of primary localized prostate cancer. The study will be divided …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    3 in total
    Run by
    SpectraCure AB

    See if you can join NCT06807359 on ClinicalTrials.gov

  22. Clinical Trial of Approaches to Prostate Cancer Surgery

    This is a prospective, randomized controlled trial to compare cancer control and health-related quality of life following pelvic fascia-sparing radical prostatectomy versus standard radical prostatectomy. The investigators hypothesize that pelvic fascia-sparing radical prostatectomy will have simil…

    Stage
    Not phased
    Ages
    40 to 80
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    9 in total
    Run by
    Weill Medical College of Cornell University

    See if you can join NCT05155501 on ClinicalTrials.gov

  23. Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

    This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune system's ability to destroy cancer cells). This study will assess whether 225Ac-J591 + pembrolizuma…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    New York Presbyterian/Weill Cornell Medical Center, New York, New York
    Locations
    4 in total
    Run by
    Weill Medical College of Cornell University

    See if you can join NCT04946370 on ClinicalTrials.gov

  24. A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

    The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells. Researchers will look at whether this treatment approach is able to c…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center (All protocol activites), New York, New York
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06347705 on ClinicalTrials.gov

  25. Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

    This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation Therapy or SBRT) as effective as usual external radiation t…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Manhattan Eye Ear and Throat Hospital, New York, New York
    Locations
    57 in total
    Run by
    Canadian Cancer Trials Group

    See if you can join NCT06235697 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.